According to Cellectis's latest financial reports the company has $67.35 M in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $97.69 M | -47.51% |
2021-12-31 | $0.18 B | -30.61% |
2020-12-31 | $0.26 B | -25.68% |
2019-12-31 | $0.36 B | -20.13% |
2018-12-31 | $0.45 B | 52.16% |
2017-12-31 | $0.29 B | 2% |
2016-12-31 | $0.29 B | -15.25% |
2015-12-31 | $0.34 B | 151.48% |
2014-12-31 | $0.13 B | 1208.83% |
2013-12-31 | $10.43 M | -63.81% |
2012-12-31 | $28.84 M | -47.5% |
2011-12-31 | $54.93 M | 71.76% |
2010-12-31 | $31.98 M | -50.48% |
2009-12-31 | $64.58 M | 61.53% |
2008-12-31 | $39.98 M | 8.84% |
2007-12-31 | $36.73 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Regeneron Pharmaceuticals REGN | $10.84 B | 16,000.24% | ๐บ๐ธ USA |
uniQure QURE | $0.61 B | 817.33% | ๐ณ๐ฑ Netherlands |
Novavax NVAX | $0.56 B | 744.01% | ๐บ๐ธ USA |
Flexion Therapeutics
FLXN | N/A | N/A | ๐บ๐ธ USA |